Lexicon Pharmaceuticals, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Lexicon Pharmaceuticals, Inc. (LXRX) holds an ST Score of 50.8 out of 100 (C+), with its strongest factor being Forecast (A) and its weakest Growth (C-). Analysts rate LXRX Hold across 14 ratings with a $6.00 average price target (+2.3% vs the current $1.86).
- Strongest
- ForecastA
- Weakest
- GrowthC-
All factor grades
- ForecastA
- ProfitabilityB+
- Financial StrengthB
- MomentumC+
- ValuationC
- GrowthC-
- Piotroski2/9
Contact
LXRX stock: frequently asked questions
What is LXRX's ST Score?
Lexicon Pharmaceuticals, Inc. (LXRX) has an ST Score of 50.8 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LXRX a buy, sell, or hold?
Wall Street's consensus rating on LXRX is Hold based on 14 analyst ratings. Our own ST Score grades it C+ (50.8/100). This is data, not investment advice — always do your own research.
What is LXRX's valuation grade?
Lexicon Pharmaceuticals, Inc. (LXRX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LXRX's growth grade?
Lexicon Pharmaceuticals, Inc. (LXRX) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LXRX's profitability grade?
Lexicon Pharmaceuticals, Inc. (LXRX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LXRX's financial strength grade?
Lexicon Pharmaceuticals, Inc. (LXRX) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LXRX?
The average analyst price target for Lexicon Pharmaceuticals, Inc. (LXRX) is $6.00 from 14 analysts, which is +2.3% versus the recent price of $1.86.
What is LXRX's Piotroski score?
Lexicon Pharmaceuticals, Inc. (LXRX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.